78 Recruiting Studies Using Enzalutamide
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Enzalutamide
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
π University of Colorado Cancer Center β Aurora, Colorado
Cancer
View Study & Checklist βStudy Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment
π Arizona Institute of Urology (AIU) - Tucson β Tucson, Arizona
Metastatic Castration-Resistant Prostate Cancer
View Study & Checklist βStudy of TGF-Ξ² Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer
π Sibley Memorial Hospital β Washington D.C., District of Columbia
Prostate Cancer
View Study & Checklist βNeoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer
π University of California, Los Angeles β Los Angeles, California
Prostate Cancer
View Study & Checklist βStudy of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer
π Research Site β Detroit, Michigan
Metastatic Prostate Cancer
View Study & Checklist βStudy of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
π Moffitt Cancer Center β Tampa, Florida
Prostate Cancer
View Study & Checklist βAn Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
π University of California San Diego - Moores Cancer Center β La Jolla, California
Metastatic Hormone-sensitive Prostate Cancer
View Study & Checklist βPROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA
π BC Cancer - Kelowna (Sindi Ahluwalia Hawkins Centre) β Kelowna, British Columbia
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
View Study & Checklist βStudy of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer
π Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) β Basking Ridge, New Jersey
Metastatic Prostate Cancer
View Study & Checklist βSaruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
π Research Site β Chandler, Arizona
Metastatic Castration-Sensitive Prostate Cancer
View Study & Checklist βStudy of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
π Exelixis Clinical Site #4 β Tucson, Arizona
Metastatic Prostate Cancer
View Study & Checklist βEnzalutamide for Patients With Androgen Receptor Positive Salivary Cancers
π Anchorage Associates in Radiation Medicine β Anchorage, Alaska
Salivary Cancer
View Study & Checklist βManagement of Castration-Resistant Prostate Cancer with Oligometastases
π BC CANCER Vancouver β Vancouver, British Columbia
Castration-resistant Prostate Cancer Patients with Oligometastases
View Study & Checklist βPreoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer
π University of Colorado β Aurora, Colorado
Breast Cancer
View Study & Checklist βSafety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
π University of Alabama at Birmingham β Birmingham, Alabama
Hormone Sensitive Prostate Cancer
View Study & Checklist βFOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer
π University of California, San Francisco β San Francisco, California
Metastatic Castration-resistant Prostate Cancer
View Study & Checklist βA Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery
π Arizona Center for Cancer Care - Gilbert β Gilbert, Arizona
Prostate Cancer
View Study & Checklist βStudy to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
π Ellison Institute β Los Angeles, California
Liposarcoma
View Study & Checklist βA Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
π Site US10052 β Anchorage, Alaska
Prostate Cancer
View Study & Checklist βPembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide
π OHSU Knight Cancer Institute β Portland, Oregon
Castration-Resistant Prostate Carcinoma
View Study & Checklist βA Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy
π Anchorage Associates in Radiation Medicine β Anchorage, Alaska
Castration-Resistant Prostate Carcinoma
View Study & Checklist βCognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer
π City of Hope Comprehensive Cancer Center β Los Angeles, California
Castration-Resistant Prostatic Cancer
View Study & Checklist βFeasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer
π Hartford Healthcare Cancer Institute @ Hartford Hospital β Hartford, Connecticut
Breast Cancer
View Study & Checklist βEnzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer
π Thomas Jefferson University β Philadelphia, Pennsylvania
Adenocarcinoma of the Prostate
View Study & Checklist βA Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
π Urology Centers of Alabama β Homewood, Alabama
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
View Study & Checklist βPhase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
π University of Alabama at Birmingham β Birmingham, Alabama
Metastatic Castration-resistant Prostate Cancer
View Study & Checklist βZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
π University of California, San Francisco β San Francisco, California
Castration-Resistant Prostate Carcinoma
View Study & Checklist βEnzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer
π Dana Farber Cancer Institute β Boston, Massachusetts
Prostatic Neoplasms
View Study & Checklist βEnzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer
π Dana Farber Cancer Institute β Boston, Massachusetts
Prostatic Neoplasms
View Study & Checklist βEnzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer
π City of Hope β Duarte, California
Castration-Resistant Prostate Carcinoma
View Study & Checklist βDetecting Metastases by PyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer.
π CHUM β Montreal, Quebec
Prostate Cancer
View Study & Checklist βPhase III Radium 223 mCRPC-PEACE III
π Hopital Universitaire Brugmann β Brussels,
Prostate Cancer
View Study & Checklist βEnzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer
π OHSU Knight Cancer Institute β Portland, Oregon
Castration-Resistant Prostate Carcinoma
View Study & Checklist βSaruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA β₯ 0.2 ng/mL (EvoPAR-PR05)
π Research Site β Ottawa, Ontario
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
View Study & Checklist βA Dose Optimization Study of Enzalutamide in Elderly Patients With Advanced Prostate Cancer
π Sunnybrook Health Sciences Centre β Toronto, Ontario
Prostate Cancer Patients
View Study & Checklist βA Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
π University of Chicago Comprehensive Cancer Center β Chicago, Illinois
Prostate Cancer
View Study & Checklist βDifluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
π Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center β Baltimore, Maryland
Prostate Cancer
View Study & Checklist βStudy of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
π City of Hope National Medical Center β Duarte, California
Prostate Cancer
View Study & Checklist βStudy of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer
π University of California, Los Angeles β Los Angeles, California
Metastatic Castration-resistant Prostate Cancer
View Study & Checklist βStudy of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
π University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0040) β Orange, California
Prostate Cancer Metastatic
View Study & Checklist βA Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
π Banner-University Medical Center Tucson β Tucson, Arizona
Metastatic Castration Resistant Prostate Cancer (mCRPC)
View Study & Checklist βAbiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
π VA Greater Los Angeles Healthcare System β Los Angeles, California
Metastatic Cancer
View Study & Checklist βPan Tumor Rollover Study
π Local Institution - 0220 β Huntsville, Alabama
Cancer
View Study & Checklist βA Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics
π Precision Point Specialty LLC PPS Analytics, a Specialty Networks LLC Company β Cleveland, Ohio
Prostatic Neoplasms
View Study & Checklist βA Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
π Florida Cancer Specialists β Sarasota, Florida
Metastatic Castration-resistant Prostate Neoplasms
View Study & Checklist βA Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
π Research Site 111 β Tucson, Arizona
Advanced Solid Tumors
View Study & Checklist βA Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
π UCLA Hematology & Oncology ( Site 0003) β Los Angeles, California
Castration-Resistant Prostatic Cancer
View Study & Checklist βCell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
π Fred Hutch/University of Washington Cancer Consortium β Seattle, Washington
Metastatic Castration-Resistant Prostate Carcinoma
View Study & Checklist βRelugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
π Northwestern University β Chicago, Illinois
Prostate Adenocarcinoma
View Study & Checklist βA Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
π University of Alabama at Birmingham β Birmingham, Alabama
Metastatic Breast Cancer
View Study & Checklist βAZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
π Research Site β Dothan, Alabama
Metastatic Castration-resistant Prostate Cancer
View Study & Checklist βPresurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer
π M D Anderson Cancer Center β Houston, Texas
Prostate Cancer
View Study & Checklist βStudy of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer
π Weill Cornell Medicine/NewYork-Presbyterian Hospital β New York, New York
Prostatic Neoplasms, Castration-Resistant
View Study & Checklist βNeoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer
π VA Portland Healthcare System β Portland, Oregon
Prostate Cancer
View Study & Checklist βTargeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
π University of Alabama at Birmingham Cancer Center β Birmingham, Alabama
Castration-Resistant Prostate Carcinoma
View Study & Checklist βA Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
π VA Greater LA Healthcare System β Los Angeles, California
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
View Study & Checklist βEnzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy
π National Institutes of Health Clinical Center β Bethesda, Maryland
Prostate Cancer
View Study & Checklist βThe Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
π Chao Family Comprehensive Cancer Centre β Orange, California
Metastatic Castration-resistant Prostate Cancer
View Study & Checklist βA Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
π GSK Investigational Site β Lake Success, New York
Neoplasms
View Study & Checklist βZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
π California Research Institute β Los Angeles, California
Metastatic Castration-Resistant Prostate Cancer
View Study & Checklist βA Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
π The University of Arizona Cancer Center - North Campus ( Site 0073) β Tucson, Arizona
Metastatic Castration-resistant Prostate Cancer (mCRPC)
View Study & Checklist βStudy of ORIC-944 in Patients With Metastatic Prostate Cancer
π Rocky Mountain Cancer Center β Colorado Springs, Colorado
Metastatic Prostate Cancer
View Study & Checklist βEnzalutamide Implants (Enolen) in Patients With Prostate Cancer
π Urology Associates of Central California β Fresno, California
Prostate Adenocarcinoma
View Study & Checklist βA Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer
π Mary Crowley Cancer Research β Dallas, Texas
Metastatic Castration-resistant Prostate Cancer (mCRPC)
View Study & Checklist βA Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
π Urology Specialists of the Carolinas - University Place β Charlotte, North Carolina
Metastatic Castration Resistant Prostate Cancer
View Study & Checklist βA Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
π VA West Los Angeles Medical Center - (CRS) - NAVREF - PPDS β Los Angeles, California
Metastatic Castration-Resistant Prostate Cancer
View Study & Checklist βSequential Testosterone and Enzalutamide Prevents Unfavorable Progression
π University of California, San Diego (UCSD) β San Diego, California
Castration Resistant Metastatic Prostate Cancer
View Study & Checklist βDocetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
π Anchorage Associates in Radiation Medicine β Anchorage, Alaska
Prostate Cancer (Adenocarcinoma)
View Study & Checklist βA Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
π Ironwood Cancer & Research Centers β Chandler, Arizona
Metastatic Castration-Resistant Prostate Cancer
View Study & Checklist βRuxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
π Rush University β Chicago, Illinois
Castration-Resistant Prostate Carcinoma
View Study & Checklist βThis Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naΓ―ve.
π Clearview Cancer Institute (Crestwood) β Huntsville, Alabama
Metastatic Castration Sensitive Prostate Cancer (mCSPC)
View Study & Checklist βA Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
π H. Lee Moffitt Cancer Center & Research Institute β Tampa, Florida
Advanced Solid Tumor
View Study & Checklist βA Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
π Central Alabama Research β Birmingham, Alabama
Metastatic Castration-resistant Prostate Cancer
View Study & Checklist βA Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
π Arizona Urology Specialists β Tucson, Arizona
Prostate Cancer
View Study & Checklist βThe COSMYC Trial (COmbined Suppression of MYC)
π Johns Hopkins Sidney Kimmel Comprehensive Cancer Center β Baltimore, Maryland
Metastatic Castration-resistant Prostate Cancer
View Study & Checklist βStereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
π Mayo Clinic in Arizona β Phoenix, Arizona
Recurrent Castration-Sensitive Prostate Carcinoma
View Study & Checklist βPhase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
π MD Anderson Cancer Center β Houston, Texas
Solid Tumor
View Study & Checklist βA Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
π Yale University (Data Collection Only) β New Haven, Connecticut
Prostate Cancer
View Study & Checklist β